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Abstract
Introduction: Omentin-1, secreted by visceral adipose tissue, has been indicated in the regulation of bone metabolism in girls with anorexia 
nervosa (AN). The aim of the study was to evaluate the relationship between omentin-1 and bone metabolism in girls with AN as well as 
the potential involvement of OPG and RANKL in this relationship.
Material and methods: Serum omentin-1, OC, CTx, OPG, and sRANKL were determined by ELISA in 49 girls with AN and in 30 healthy 
controls, aged 13 to 17 years.
Results: Girls with AN exhibited significant reduction in body weight, BMI, and Cole index as well as a significant increase in serum 
omentin-1 levels, compared to healthy participants. These changes were associated with a significant decrease in serum OC and CTx levels 
and a significant increase in OPG and sRANKL while the OC/CTx and OPG/sRANKL ratios were significantly decreased. BMI and the 
Cole index correlated negatively and significantly with omentin-1 levels, positively with CTx levels and the OC/CTx ratio in the control 
group (C), girls with AN, and all study participants (C + AN). Girls with AN showed a significant negative correlation between BMI, the 
Cole index, and OPG levels. The combined group (C + AN) showed a significant positive correlation between BMI, the Cole index, and 
the OPG/sRANKL ratio. Omentin-1 levels correlated negatively and significantly with OC and CTx levels as well as with the OC/CTx and 
OPG/sRANKL ratios in the C, AN, and C + AN groups.
Conclusions: The relationship between omentin-1, bone markers, and the OC/CTx and OPG/sRANKL ratios observed in girls with AN 
indicates the involvement of this adipokine in the regulation of dynamic balance between bone formation and resorption processes. 
Omentin-1 might exert a negative effect on bone remodelling in girls with AN by inhibiting both bone formation and resorption. The 
OPG/sRANKL system plays an important role in the latter. (Endokrynol Pol 2015; 66 (6): 514–520)
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Streszczenie
Wstęp: Sugeruje się, że omentyna-1 produkt wisceralnej tkanki tłuszczowej, może współuczestniczyć w regulacji metabolizmu kostne-
go u dziewcząt z jadłowstrętem psychicznym (AN). Celem pracy była ocena związku między omentyną-1 a metabolizmem kostnym 
u dziewcząt z AN z uwzględnieniem ewentualnego udziału OPG i RANKL w mechanizmie powiązań między nimi. 
Materiał i metody: U 49 dziewcząt z AN i 30 zdrowych w wieku 13–17 lat oceniono stężenia omentyny-1, OC, CTx, OPG i sRANKL 
w surowicy metodą ELISA. 
Wyniki: U dziewcząt z AN wykazano istotne zmniejszenie masy ciała, wskaźnik masy ciała (BMI), wskaźnika Cole’a oraz znamienny wzrost 
stężenia omentyny-1 w surowicy w porównaniu z grupą dziewcząt zdrowych. Zmianom tym towarzyszyła znamienna supresja stężeń OC, 
CTx oraz wzrost stężeń OPG i sRANKL w surowicy przy istotnie obniżonych wartościach wskaźników OC/CTx i OPG/sRANKL. Wartości 
wskaźników BMI i Cole’a korelowały istotnie ujemnie ze stężeniami omentyny-1 oraz dodatnio ze stężeniami CTx i wartościami wskaźnika 
OC/CTx w grupie kontrolnej (C), u dziewcząt z AN i u wszystkich dziewcząt łącznie (grupa C + AN). Znamienną ujemną korelację między 
wartościami wskaźników BMI i Cole’a a stężeniami OPG stwierdzono w grupie dziewcząt z AN. U dziewcząt grupy C + AN wykazano 
natomiast istotną dodatnią korelację między wartościami wskaźników BMI i Cole’a a wskaźnikiem OPG/sRANKL. Stężenia omentyny-1 
korelowały istotnie ujemnie ze stężeniami OC, CTx i wartościami wskaźników OC/CTx i OPG/sRANKL w grupach: C, AN oraz C + AN. 
Wnioski: Wykazana zależność między omentyną-1 a markerami kostnymi oraz wskaźnikami OC/CTx i OPG/sRANKL u dziewcząt z AN 
wskazuje na udział tej adipokiny w regulacji dynamicznej równowagi między procesami kościotworzenia i resorpcji kości. Omentyna-1 
działa niekorzystnie na remodeling kostny u dziewcząt z AN wpływając zarówno na tworzenie tkanki kostnej, jak i jej resorpcję. W tym 
ostatnim mechanizmie istotną rolę odgrywa układ OPG/sRANKL.  (Endokrynol Pol 2015; 66 (6): 514–520)
Słowa kluczowe: jadłowstręt psychiczny; dziewczęta; omentyna-1; metabolizm kostny; OPG; sRANKL 
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exert a negative effect on bone mass by inhibiting bone 
formation in girls with AN. To our knowledge, neither 
the relationship between serum omentin-1 and OPG 
and/or RANKL levels nor the relationship between 
omentin-1 and OC/CTx and/or OPG/sRANKL ratios 
have been assessed in girls with AN. The OC/CTx or 
CTx/OC ratios have been widely used as indices of bone 
remodelling balance [21,22]. The relative OPG/RANKL 
balance is important in maintaining an appropriate ba-
lance of bone remodelling [9, 10, 23–29]. Munoz-Calvo 
et al. [23] and our previous studies in girls with AN [26] 
demonstrated that the OPG/RANKL ratio may prove 
to be a more relevant marker in predicting bone loss 
compared to absolute levels of these factors. Thus we 
investigated the relationship between omentin-1 and 
bone remodelling as assessed by serum osteocalcin (OC, 
a marker of bone formation), C-terminal telopeptide 
of type I collagen α 1 chain (CTx, a marker of bone 
resorption), and the OC/CTx ratio, as well as potential 
participation of OPG, its soluble ligand sRANKL, and 
the OPG/sRANKL ratio in this relationship.
Material and methods
The study group consisted of 49 girls aged 13 to 17 years, 
hospitalised at the Paediatric Department in Zabrze, 
who, following examinations by paediatricians and 
a psychiatrist, were diagnosed with AN based on the 
American Psychiatric Association’s classification and 
diagnostic tool, i.e. the DSM-IV of 1994. Girls with AN 
underwent all tests during the first three days of hospi-
tal stay, that is prior to the launch of therapy. All other 
somatic or mental disorders that might lead to cachexia 
were ruled out. The mean age of the AN patients was 
15.43 ± 0.87 years (Table I). All had secondary amenor-
rhea. The duration of the disease was 3–60 months. 
The control group consisted of 30 healthy, regularly 
menstruating girls (mean age 15.39 ± 0.92 years) with no 
endocrine or other disorders that could affect bone tis-
sue metabolism; they were all schoolgirls from the city 
of Zabrze, who volunteered to participate in the study.
The height and body weight of all participants were 
measured, and their body mass index (BMI) calculated. 
The mean body weight of girls with AN was 38.67 ± 2.01 
kg, and mean BMI was 15.91 ± 2.17 kg/m2. The Cole 
index was also calculated, which reflects the nutritional 
status of an individual and encompasses the following 
categories: wasting — < 75%; undernourished — 
75–85%; mildly undernourished – 85-90%; adequately 
nourished — 90–100%; overnourished — > 110% [acc. 
to 30]. The mean value of the Cole index in AN patients 
was 76.30 ± 0.19%. The mean body weight of the control 
participants was 58.21 ± 4.79 kg, BMI 20.63 ± 2.19 kg/m2, 
and Cole index 102.10 ± 0.18% (Table I).
Introduction
Adipose tissue plays an important role in the regula-
tion of bone metabolism [1–4]. It has been shown that 
adipose tissue-derived adipokines including leptin, 
adiponectin, resistin, visfatin, or apelin are capable 
of modulating bone metabolism both in vitro and in 
vivo [1, 4]. Recent studies indicate that a novel visceral 
adipose tissue-derived adipokine, omentin-1 [5], might 
also participate in the regulation of bone metabolism. 
In vitro studies revealed that omentin-1 inhibited os-
teoblast differentiation [6]. In co-culture systems, it 
reduced osteoclast formation, probably via its effect on 
osteoprotegerin (OPG) and receptor activator of nuclear 
factor κB ligand (RANKL) production in osteoblasts [7, 
8]. Dysregulation of this cytokine system is thought to 
underlie bone loss due to different somatic disorders 
[9, 10].
There are very few human studies confirming the 
effect of omentin-1 on bone tissue. Omentin-1 level 
appears to be significantly higher in pre- compared to 
postmenopausal women. It was also shown that total 
body mass, lean mass, and omentin-1 were independ-
ent predictors of bone mineral density (BMD) at the 
spine, total hip, and femoral neck [11]. In premeno-
pausal women, a negative and significant correlation 
was found between omentin-1 and bone formation 
and resorption markers. However, omentin-1 was not 
a BMD predictor in postmenopausal women [11]. Tohidi 
et al. [12] reported that, in postmenopausal women, 
omentin-1 levels were significantly correlated with 
BMD at the lumbar spine but did not correlate with 
femoral neck BMD.
Since Wang et al. [11] found that body weight, BMI, 
and lean mass might modulate the effect of omentin-1 
on bone metabolism in premenopausal women, a few 
researchers [13–20] have undertaken investigations into 
the relationship between omentin-1 and the determi-
nants of the nutritional status and/or bone metabolism 
and BMD in individuals with eating disorders. Obese 
individuals exhibited a decrease in omentin-1 level 
compared to those with normal weight [13–16, 18–20], 
while in AN patients an increase in serum omentin-1 
level was shown [17, 20]. Changes in omentin-1 level 
were negatively and significantly correlated with body 
weight and BMI both in obese [13–16, 20] and in AN 
patients [17, 20]. In girls with AN, the relationship be-
tween omentin-1, bone metabolism, and BMD at lumbar 
spine and total hip was only studied by Guo et al. [17]. 
They found significant negative correlations between 
this adipokine and BMD as well as bone formation and 
resorption markers. They also revealed that omentin-1, 
BMI, and lean mass were independent predictors of 
BMD. Guo et al. [17] concluded that omentin-1 might 
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On the day of the examination the girls did not 
report any complaints; none of them suffered from 
an acute infection during the preceding month. Blood 
samples for the determination of omentin-1, OC, CTx, 
OPG, and sRANKL were collected between 08.00 and 
09.00 hours after a 12-hour fast. Centrifuged serum 
was frozen and stored at –75°C until assay. Determi-
nations of omentin-1, OC, CTx, OPG, and sRANKL 
levels were performed using High-Sensitivity Hu-
man ELISA kits: omentin-1 (BioVendor – Laboratorni 
Medicina a.s., Czech Republic), OC (DSL Inc., USA), 
CTx (Nornic Bioscience Diagnostics A/S, Denmark), 
OPG, and sRANKL (Biomedica, Austria). The respec-
tive sensitivity, intra- and interassay errors were: 
0.5 ng/mL, 3.7 and 4.6% for omentin-1; 0.05 mmol/L, 
5.8 and 7.3% for OC; 0.08 nmol/L, 5.2 and 6.7% for 
CTx; 0.14 pmol/L, 7 and 7.5% for OPG; 0.04 pmol/L, 
5 and 7% for sRANKL.
The database was prepared using Excel 2000 (Mi-
crosoft Corporation). Statistical analysis was carried 
out with Statistica 10 for Windows (StatSoft Inc., USA). 
The Student t-test was used to determine the signifi-
cance of intergroup differences (normal distribution 
of variables). In the case of non-normal distribution, 
the significance was tested using the Mann-Whitney 
U test. The relationships between the BMI and Cole 
indexes, omentin-1, OC, CTx, OPG, sRANKL levels, 
and the OC/CTx and OPG/sRANKL ratios in control 
participants (C), girls with AN, and the combination 
group of C + AN were analysed using Spearman’s 
correlation. The level of significance was set at p ≤ 0.05.
The study was approved by the Bioethics Com-
mittee of the Silesian Medical University in Katowice 
(KNW/0022/KB1/105/09). Informed consent to partici-
pate in the study was obtained from the patients, their 
parents, or guardians.
Results
The mean age of AN girls was comparable to that of the 
control participants (Table 1). The mean body weight, 
BMI, and Cole index were significantly lower in girls 
with AN compared to healthy controls. The mean 
serum omentin-1, on the other hand, was significantly 
higher in the AN group. The changes in the mean 
level of omentin-1 were associated with considerable 
suppression of the mean serum levels of OC and CTx 
and elevation of the mean OPG and sRANKL levels 
compared to healthy participants, while the OC/CTx 
and OPG/sRANKL ratios were significantly decreased 
(Table I).
In the control participants, girls with AN, and the 
total study population (C + AN), BMI and the Cole 
index were negatively and significantly correlated 
with omentin-1 levels, while their correlation with CTx 
and the OC/CTx ratio was positive. Girls with AN had 
a significant negative correlation between BMI, the Cole 
index, and OPG. The control and AN groups (C + AN) 
exhibited a significant positive correlation between BMI 
and the OPG/sRANKL ratio (Table II).
A significant negative correlation was revealed be-
tween omentin-1 and OC, CTx levels as well as between 
omentin-1 and the OC/CTx and OPG/sRANKL ratios 
in the total study population and also in the individual 
groups (AN, C) (Table III).
Discussion
Recent in vitro and in vivo studies indicate that 
omentin-1, secreted predominantly by visceral adipose 
tissue, is an important modulator of bone metabolism 
[6–8, 11, 12, 17, 31].
Table I. Mean values of age, body weight, height, body mass 
index (BMI), the Cole index, mean serum levels of omentin-1, 
osteocalcin (OC), C-terminal telopeptide of type I collagen α 1 
chain (CTx), osteoprotegerin (OPG), soluble receptor activator 
of nuclear factor-kB ligand (sRANKL), and mean values of 
the OC/CTx and OPG/sRANKL ratios in girls with anorexia 
nervosa and in the control group
Tabela I. Średni wiek, masa ciała, wzrost, wskaźnik masy 
ciała (BMI), wskaźnik Cole’a, średnie stężenia omentyny-1, 
osteokalcyny (OC), C-terminalnego usieciowanego telopeptydu 
łańcucha α 1 kolagenu typu I (CTx), osteoprotegeryny (OPG), 
rozpuszczalnego ligandu receptora aktywatora czynnika 
jądrowego-kB (sRANKL) oraz wartości wskaźników OC/ 
/CTx i OPG/sRANKL w grupie kontrolnej i u dziewcząt 
z jadłowstrętem psychicznym
Variables Groups
Control group 
(n = 30)
Anorexia nervosa 
(n = 49)
Age (years) 15.39 ± 0.92 15.43 ± 0.87
Height [m] 1.63 ± 0.05 1.61 ± 0.06
Body mass [kg] 58.21 ± 4.79 38.67 ± 2.01*
BMI [kg/m2] 20.63 ± 2.19 15.91 ± 2.17*
Cole index (%) 102.10 ± 0.18 76.30 ± 0.19*
Omentin-1  
[ng/mL]
139.45 ± 15.41 184.23 ± 25.20*
OC [μmol/L] 4.32 ± 3.05 2.12 ± 3.19*
CTx [nmol/L] 5.91 ± 3.51 3.55 ± 2.50*
OC/CTx ratio  
[μmol/L/nmol/L]
0.93 ± 0.10 0.65 ± 0.08*
OPG [pmol/L] 3.39 ± 1.29 4.69 ± 1.61*
sRANKL [pmol/L] 0.26 ± 0.08 0.31 ± 0.09*
OPG/sRANKL ratio 12.36 ± 1.12 8.88 ± 1.05*
*p ≤ 0.05 vs. control group
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Omentin-1 stimulates proliferation and inhibits 
differentiation of mouse osteoblasts in vitro [6]. It 
also induces human osteoblast proliferation — most 
probably through the PI3K/Akt signal pathway [31]. 
In the co-culture system of osteoblasts and osteoclasts 
precursors, omentin-1 also reduced osteoclasts forma-
tion by stimulating OPG and inhibiting RANKL pro-
duction in osteoblasts [7, 8]. Xie et al. [7] showed that 
omentin-1 reduces serum RANKL, tartrate-resistant 
acid phosphatase (TRAP) and OC levels, which in-
crease dramatically in OPG knockout (OPG–/–) mice. 
Adenovirus-mediated overexpression of omentin-1 
partially restored BMD and bone strength in ovariecto-
mised mice. This was associated with decreased levels 
of serum OC and TRAP and lower serum RANKL/ 
/OPG ratio [8].
The data above seem to suggest that omentin-1 
might play a role in the regulation of bone remodel-
ling — also in humans. Its effect might be modulated 
by cytokines of the RANKL/RANK/OPG system. How-
ever, the relationship between omentin-1 and bone 
markers, and especially between omentin-1 and OPG, 
RANKL and the OPG/RANKL ratio in humans, has 
been studied only by a few researchers. Tohidi et al. 
[12] reported that circulating omentin-1 level had an 
inverse correlation with BMD at the lumbar spine in 
Iranian postmenopausal women. Wang et al. [11] study 
in pre- and postmenopausal women demonstrated 
that the effects of omentin-1 on bone metabolism 
depend on the menopausal status. They showed that 
omentin-1 was significantly negatively correlated with 
bone-specific alkaline phosphatase (BAP) and NTx, 
and was an independent negative predictor of BMD 
at lumbar spine, total hip, and femoral neck only in 
premenopausal Chinese women. Body weight, BMI, 
and lean mass were also independent BMD predic-
Table II. Correlation between body mass index (BMI), the 
Cole index and omentin-1, osteocalcin (OC), C-terminal 
telopeptide of type I collagen α 1 chain (CTx), osteoprotegerin 
(OPG), soluble receptor activator of nuclear factor-kB ligand 
(sRANKL) and the OC/CTx and OPG/sRANKL ratios in the 
control group (C), in girls with anorexia nervosa (AN), and 
in all girls (C + AN)
Tabela II. Korelacja między wskaźnikiem masy ciała (BMI), 
wskaźnikiem Cole’a a omentyną-1, osteokalcyną (OC), 
C-terminalnym usieciowanym telopeptydem łańcucha α 1 
kolagenu typu I (CTx), osteoprotegeryną (OPG), rozpuszczalnym 
ligandem receptora aktywatora czynnika jądrowego-kB 
(sRANKL) i wartościami wskaźników OC/CTx i OPG/ 
/sRANKL w grupie kontrolnej (C), u dziewcząt z jadłowstrętem 
psychicznym (AN) i u wszystkich dziewcząt łącznie (C+AN)
Variables Values of correlation coefficients
C 
(n = 30)
AN 
(n = 49)
C + AN 
(n = 79)
BMI [kg/m2] Omentin-1 [ng/mL] –0.352* –0.524* –0.422*
OC [μmol/L] NS NS NS
CTx [nmol/L] 0.492* 0.303* 0.334*
OC/CTx ratio
[μmol/L/nmol/L]
0.400* 0.649* 0.423*
OPG [pmol/L] NS –0.759* NS
sRANKL [pmol/L] NS NS NS
OPG/sRANKL ratio NS NS 0.268*
Cole index (%) Omentin-1 [ng/mL] –0.524* –0.615* –0.503*
OC [μmol/L] NS NS NS
CTx [nmol/L] 0.520* 0.330* 0.332*
OC/CTx ratio
[μmol/L/nmol/L]
0.455* 0.651* 0.520*
OPG [pmol/L] NS –0.308* NS
sRANKL [pmol/L] NS NS NS
OPG/sRANKL ratio NS NS 0.254*
*p ≤ 0.05 — statistically significant values of correlation coefficients
Table III. Correlation between omentin-1 and osteocalcin (OC), C-terminal telopeptide of type I collagen α 1 chain (CTx), 
osteoprotegerin (OPG), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and the OC/CTx and OPG/sRANKL 
ratios in the control group (C), girls with anorexia nervosa (AN), and all girls studied (C + AN)
Tabela III. Korelacja między omentyną-1 a osteokalcyną (OC), C-terminalnym usieciowanym telopeptydem łańcucha α 1 
kolagenu typu I (CTx), osteoprotegeryną (OPG), rozpuszczalnym ligandem receptora aktywatora czynnika jądrowego-kB 
(sRANKL) i wartościami wskaźnika OPG/sRANKL w grupie kontrolnej (C), u dziewcząt z jadłowstrętem psychicznym (AN) 
i u wszystkich dziewcząt łącznie (C + AN)
Variables Bone markers OC/CTx ratio 
[μmol/L/nmol/L]
Cytokines of RANKL/RANK/OPG system OPG/sRANKL 
ratio
Groups
OC 
[μmol/L]
CTx 
[nmol/L]
OPG [pmol/L] sRANKL [pmol/L]
Omentin-1 
[ng/mL]
–0.410* –0.366* –0.350* NS NS –0.360* C (n = 30)
–0.391* –0.354* –0.277* NS NS –0.481* AN (n = 49)
–0.521* –0.487* –0.230* NS NS –0.387* C + AN (n = 79)
*p ≤ 0.05 — statistically significant values of correlation coefficients
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tors in these women. However, in postmenopausal 
women, years after menopause, BMI, lean mass, 
estradiol, and adiponectin (but not omentin-1) were 
independent predictors of BMD. Omentin-1 level is 
significantly lower in post- than in premenopausal 
women and its effect on bone metabolism might be 
smaller. Differences in oestrogen levels caused by the 
menopause status may also contribute to the influence 
of omentin-1 on BMD in Chinese women [11]. High 
BMI is known to be a protecting factor against exces-
sive bone loss in aging, and higher BMI is associated 
with a slower rate of bone loss [32]. Omentin-1 level 
decrease in obese patients and increase after weight 
loss; these changes are positively correlated with 
adiponectin and negatively correlated with BMI and 
leptin [13–16, 18–20]. In patients with AN, an increase 
in serum omentin-1 levels was shown compared to 
healthy controls, correlating negatively with body 
weight and BMI [17, 20]. Guo et al. [17] studied girls 
with AN and found that omentin-1 was negatively 
and significantly correlated with total body, lumbar 
spine, and total hip BMD. They also showed that BMD 
at various skeletal regions correlated negatively and 
significantly with adiponectin and positively with 
leptin. Several independent variables were entered 
in the regression analysis models, including age, BMI, 
fat mass, lean mass, serum 25-hydroxyvitamin D (the 
best indicator of vitamin D), estradiol, omentin-1, 
adiponectin, and leptin levels. In models with total 
body, lumbar spine, and total hip BMD as the depend-
ent variables, the significantly independent variables 
for the total study population and individual groups 
were omentin-1, lean mass, 25-hydroxyvitamin D, and 
BMI. Guo et al. [17] also found that omentin-1 was 
negatively and significantly correlated with BAP and 
NTx, both in the AN group and in the healthy group. 
This suggested that omentin-1 might play a role both 
in the AN group and in the healthy group. However, 
the omentin-1 level in girls with AN was higher than 
in girls with proper body weight, which indicated that 
omentin-1 might play a role in the decreased BMD in 
these patients.
Similar to our previous studies [20], a significant re-
duction in body weight, BMI, and Cole index observed 
in girls with AN was associated with an increase in se-
rum omentin-1 compared to healthy participants. The 
present study also revealed significant suppression of 
OC and CTx levels and elevation of serum OPG and 
sRANKL along with a decrease in the OC/CTx and 
OPG/sRANKL ratios. In the total study population 
and individual groups, the BMI and Cole index were 
negatively and significantly correlated with omentin-1 
levels, while their correlation with CTx and the OC/ 
/CTx ratio was positive. On the other hand, a negative 
significant correlation between BMI, Cole index, and 
OPG levels was found in girls with AN, while the total 
study population showed a positive significant cor-
relation between BMI, Cole index, and OPG/sRANKL 
ratio. The highest correlation coefficients were generally 
found in the AN group. The obtained results indicate 
that undernourishment might be a cause of the abnor-
malities in serum levels of omentin-1 and bone status 
indicators observed in girls with AN.
Similarly to Guo et al. [17], we also found a negative 
significant correlation between omentin-1 levels and 
bone metabolism markers (OC and CTx) in the total 
study population and individual groups. Guo et al. 
[17] suggest that omentin-1 may have a negative effect 
on bone mass only by inhibiting bone formation. The 
hypothesis was put forward by Duan et al. [6] and Xie 
et al. [7, 8] based on results of experimental studies. 
Guo et al. [17] believe that omentin-1 might act via 
indirect suppression of osteoclastogenesis, through 
stimulating OPG secretion and inhibition of RANKL in 
osteoblasts. It might also exert a direct effect via inhibi-
tion of osteoblast differentiation. However, it should 
be emphasised that Guo et al. [17] did not evaluate 
OPG and sRANKL levels or the OPG/sRANKL ratio in 
girls with AN, which might allow better clarification 
of omentin-1 action on bone tissue. Our results in girls 
with AN indicate that omentin-1 might exert a nega-
tive effect on bone metabolism by inhibiting both bone 
formation and resorption. The negative effect of omen-
tin-1 is more noticeable with respect to bone formation 
than bone resorption, as reflected by a significant de-
crease in the OC/CTx ratio in girls with AN, negatively 
and significantly correlated with omentin-1 level. On 
the other hand, our previous and present studies of 
girls with AN demonstrated an increase in OPG and 
sRANKL levels (more pronounced regarding sRANKL 
than OPG), which resulted in a significant decrease in 
the OPG/sRANKL ratio. Our previous investigations 
also revealed a negative correlation between CTx and 
sRANKL [26]. In the present study, omentin-1 levels 
correlated negatively and significantly not only with 
bone markers and the OC/CTx ratio but also with the 
OPG/sRANKL ratio in both the total study population 
and in individual groups.
The increase in OPG and sRANKL along with the 
decrease in OC and CTx is difficult to account for, espe-
cially if there are similar negative correlations between 
omentin-1 and both marker groups. It might be associ-
ated with changes in the levels of several osteotropic 
factors, mainly hormones and cytokines (especially 
melatonin, hormones of the calciotropic, somatotropic, 
pituitary-ovarian, -thyroid, -adrenal axes as well as 
changes in the production of some pro-inflammatory 
cytokines or adipose tissue hormones), which have 
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been observed in girls with AN in response to RANKL 
expression [25, 27–29, 33–37]. It has been established 
that RANKL expression in osteoblasts and osteogenic 
stromal stem cells is stimulated by growth hormone, 
parathormone, vitamin D, cortisol, prostaglandin 
E2, interleukin (IL)-1, IL-6, IL-8, IL-11, IL-17, tumour 
necrosis factor α, and is inhibited by oestrogens, an-
drogens, leptin, melatonin, IL-4, IL-10, IL-13, IL-18, 
interferon γ, and transforming growth factor β, thus 
modifying serum levels of bone resorption markers 
[9, 10]. Moreover, some of the above-mentioned fac-
tors might directly affect osteoclastogenesis, metabolic 
activity and/or osteoclast survival. On the other hand, 
changes in the levels of several osteotropic factors may 
modify the effect of omentin-1 on the dynamic balance 
between bone formation and resorption and/or the 
expression of OPG and/or RANKL. Previous investiga-
tions indicate that the mechanism might primarily be 
affected by several adipokines, including adiponectin 
and leptin as well as oestrogens and 25-hydroxyvita-
min D [11, 13, 15, 17, 23, 29, 34]. The above-mentioned 
modulators, which not only affect bone resorption but 
also bone formation, might lead to desynchronisation 
of the relationship between bone markers and OPG, 
sRANKL, and the OPG/sRANKL ratio. Low values 
of OPG/sRANKL ratio in association with high OPG 
and sRANKL levels and desynchronisation of the re-
lationship with bone markers (especially CTx) seem to 
suggest that girls with AN may suffer from an imbal-
ance of bone remodelling events or mechanism com-
pensating for bone remodelling enhancement. In our 
stepwise regression model including age, BMI, OPG, 
sRANKL, and the OPG/sRANKL ratio, only the latter 
was a significant independent predictor of serum OC 
and CTx values [26]. OC and CTx suppression coupled 
with OPG levels elevation might indicate a compensa-
tory mechanism suppressing the osteoclastic activity 
in adolescents with AN to preserve bone density [38]. 
The above data seem to confirm the hypothesis that 
omentin-1 plays and important role in the regulation 
of bone metabolism in girls with AN, also via its effect 
on the balance of the OPG/sRANKL system.
Conclusions
The relationship between omentin-1, bone markers, 
and OC/CTx and OPG/sRANKL ratios observed in girls 
with AN indicates the involvement of this adipokine in 
the regulation of the dynamic balance between bone 
formation and resorption processes.
Omentin-1 negatively influences bone turnover in 
girls with anorexia nervosa, affecting both bone tissue 
formation and resorption. The OPG/sRANKL system 
plays an important role in the latter process.
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